<DOC>
	<DOC>NCT02125266</DOC>
	<brief_summary>This study is intended to evaluate the safety of V404 PDS in patients with chronic non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide clinically measurable benefit over an extended period of time in patients with chronic non-infectious uveitis.</brief_summary>
	<brief_title>Safety and Preliminary Efficacy Study of V404 PDS in Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>18 years of age or older Confirmed diagnosis of active uveitis Sufficient lens/media clarity Meet bestcorrected visual acuity criteria Willing and able to use contraception Pregnant, breast feeding Uncontrolled glaucoma Intraocular surgery or periocular/intraocular injections within 6 weeks Periocular or intraocular steroid within 3 months Prior vitrectomy Prior corneal transplant Prior fluocinolone implant Allergy or sensitivity to study drug Participation in other trial within 30 days Abnormal liver function History of positive serum tuberculosis test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>